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Abstract
Central nervous system tumors are the leading cause of cancer related death in children. Despite 
much progress in the field of pediatric neurooncology, modern combination treatment regimens 
often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, 
secondary malignancies, and a host of other chronic health problems. Precision medicine strategies 
applied to pediatric neurooncology target specific characteristics of individual patients’ tumors to 
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achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we 
review emerging trends and the current literature that have guided the development of new 
molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and 
delivery platforms for the treatment of pediatric central nervous system tumors.
Graphical Abstract
Keywords
Precision medicine; pediatrics; neurooncology; review
Neoplasms of the central nervous system (CNS) constitute the majority of solid tumor 
diagnoses and remain the leading oncologic cause of mortality in children.1, 2 Aggressive 
multimodal treatments have yielded demonstrable improvements in survival in some cases.3 
However, the particular susceptibility of the pediatric population to the long-term effects of 
these treatments is well documented, necessitating refinement of treatment protocols.4, 5 
Late effects of existing chemotherapies and photon irradiation in young children include 
cognitive decline, endocrine dysfunction, secondary malignancy, vasculopathy, and other 
factors that impact quality of life significantly.6-8 Further, these outcomes may be 
progressive and irreversible, especially in patients aged 5 years or younger.4
The importance of tailoring therapies to address the requirements of the developing pediatric 
patient is a unique challenge. As it is recognized that CNS neoplasms found primarily in 
children harbor molecular and genetic signatures vastly different from those found in adult 
patients, the application of precision medicine in the diagnosis and management of pediatric 
CNS malignancies has received increased attention.9 In this Review, we highlight the impact 
that advances in precision medicine are making within pediatric neurooncology to drive 
progress in the development of innovative imaging and molecular technologies that achieve 
improved detection and targeting of CNS tumors. Insights gained from these efforts have 
motivated the updated World Health Organization (WHO) classification system for CNS 
tumors and led to the expanded role of next-generation profiling techniques to address 
heterogeneity and variability between tumors of a particular subgroup. In turn, these data are 
applied increasingly to guide the design of new targeted treatments, including emerging 
molecular, radiation, and immunotherapeutic strategies. Finally, to stimulate broader 
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interactions between experts in the physical and neurosciences with clinician colleagues, we 
review nanoscale platforms such as polymeric nanoparticles (PNPs), liposomes, nanoparticle 
albumin-bound technology, and molecular targeted nano-particles, which are currently being 
explored as therapeutic options for CNS tumors.10-18
CLASSIFICATION
The revised 2016 WHO system of classification for CNS neoplasms reflected a dramatic 
change in the characterization of CNS tumors. For the first time, molecular parameters were 
incorporated into a system that previously relied entirely on histology, demonstrating the 
capability for increasingly precise categorization availed by modern diagnostic techniques.19 
The three most common categories of pediatric CNS malignancies are embryonal tumors, 
which are comprised primarily of medulloblastoma, gliomas, and ependymal tumors (Figure 
1).20 Of these, gliomas and medulloblastomas underwent major restructuring under the new 
WHO classification system, whereby all three incorporated genetically defined entities that 
are highlighted below. It is hoped that the 2016 CNS WHO system will improve diagnostic 
accuracy, leading to more precise therapeutic planning (which will be detailed in a later 
section) and, ultimately, better outcomes for patients with brain tumors.
Medulloblastomas.
Medulloblastomas are currently divided into four distinct histologic and molecular 
subgroups: Wnt, Sonic Hedgehog (SHH), group 3, and group 4;21, 22 however, the clinical 
behavior of these malignancies remains heterogeneous. Integrated analyses have defined 
clinically significant subtypes within these subgroups, which may enable improved risk 
stratification over existing schema and more tailored treatment decisions.23 As an example, 
infant medulloblastoma is currently partitioned into two groups by histologic findings; 
however, there appears to be no difference in prognosis between the two strata. By 
combining gene expression with DNA methylation data, Cavalli et al. identified four infant 
SHH molecular subtypes with significant differences in survival.24 Two of these subtypes 
appear to be extremely low risk and may benefit from de-escalation of therapy in future 
clinical trials, sparing them from the adverse effects of more aggressive treatment regimens. 
These findings indicate that more in-depth studies directed at unraveling the heterogeneities 
observed within the medulloblastoma landscape are needed to establish more precise 
stratification schemes that better define risk and enable patient-specific guidance.
Gliomas.
Pediatric high-grade gliomas (HGGs) are composed primarily of anaplastic astrocytomas 
and glioblastoma and are associated with particularly poor prognoses, with 5-year survival 
rates of less than 20%. The 2016 CNS WHO classification system incorporated molecular 
variants of high-grade gliomas, including IDH-wildtype and IDH mutant glioblastoma, and 
H3.3K27M mutant diffuse midline glioma (which includes tumors previously referred to as 
diffuse intrinsic pontine glioma, DIPG).19 Due to their relative rarity, pediatric HGGs have 
traditionally been treated based on proven adult regimens, with minimal clinical benefit.
25, 26
 Researchers have found that while phenotypically indistinguishable, pediatric HGGs 
manifest characteristic genetic alterations distinct from those seen in adult HGGs.27 Next-
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generation sequencing has revealed that somatic mutations in genes encoding histones are 
characteristic of pediatric high-grade gliomas, specifically H3F3A (replication-independent 
histone 3 variant H3.3) as well as in histone 3.1, whereas IDH mutant gliomas are extremely 
rare.28 In addition, ATRX (α-thalassemia/mental retardation syndrome X-linked) and 
DAXX (death-domain associated protein) in combination with TP53 mutations are 
frequently seen in pediatric HGGs.28, 29 Furthermore, approximately 80% of pediatric 
GBMs demonstrate activation of the PI3K/Akt/mTOR pathway;30 mutations in epidermal 
growth factor receptor (EGFR) 31 and platelet-derived growth factor receptor (PDGFR) 27, 32 
have also been associated. Thus, newer molecular diagnostic techniques make it evident that 
histopathologically identical entities such as pediatric HGG may harbor profoundly 
different, potentially targetable underlying mechanisms.
Diffuse midline glioma is a malignant, infiltrative glial neoplasm of the ventral pons 
associated with a dismal outcome. Patients present with rapid onset of symptoms, and the 
median survival is 9–12 months. Most patients do not live 2 years past diagnosis and 
chemotherapy has been ineffective. Radiation is considered the standard of care and is 
utilized for extension of the symptom-free period but no therapy has yet significantly 
changed overall outcome. Recent innovations in biopsy of the pons have resulted in 
fascinating new molecular findings in this disease. Investigators have identified that 80% of 
diffuse midline glioma cases harbor histone 3.3 or 3.1 mutations, most frequently 
H3.3K27M.33 These mutations result in hypomethylation of H3 proteins and alter epigenetic 
regulation of genes crucial for cell cycle function and oncogenesis. These histone mutations 
also co-occur predictably with other mutations.33-36 For example, H3.1 mutations co-occur 
with ACVR1 mutations most commonly while H3.3 mutations co-occur with p53 and 
PDGFRA mutations. Other accessory driver mutations have been identified including 
mutations in PIK3R1 and PIK3CA. H3.3K27M mutations, independent of histopathological 
features, are universally associated with poor survival outcomes in diffuse midline glioma; in 
fact, tumors possessing these anamolies were deemed a distinct entity in the 2016 WHO 
classification system. Researchers are searching for and studying targeted therapies actively.
Low-grade gliomas (LGGs), defined in the 2007 WHO CNS classification system as grades 
I and II based on histological criteria,37 comprise the most common type of pediatric CNS 
tumor.20 A heterogeneous group, LGGs consist of oligodendroglioma, pilocytic 
astrocytoma, subependymal giant cell astrocytoma, angiocentric glioma, and others. As a 
whole, pediatric LGGs are associated with excellent long-term survival compared to adults.
38, 39
 While many historical studies treated LGGs as a single cohort, advances in molecular 
characterization techniques bolster support for individualized stratification to minimize long-
term treatment-related morbidities. For instance, neurofibromatosis type 1, a genetic 
syndrome caused by a mutation in the neurofibromin 1 gene, is associated with pilocytic 
astrocytoma and diffusely infiltrating astrocytoma40 and a number of other malignancies that 
may be amenable to biologically targeted treatments.41 Pilocytic astrocytomas have been 
found to harbor mutations in BRAF, neurotrophic tyrosine kinase type 2 (NTRK2), and 
histone H3; all of which are being specifically targeted in current pediatric clinical trials.
42, 43
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Ependymal Tumors.
Ependymoma is the third most common pediatric brain tumor type, and is frequently 
associated with poor long-term survival outcomes.44 The 2016 WHO classification system 
divides ependymal tumors into subependymoma, myxopapillary ependymoma; 
ependymoma; anaplastic ependymoma; and ependymoma, RELA fusion-positive. 
Ependymomas that have undergone chromo-thripsis (identified by the C11orf95-RELA 
fusion) were the lone genetically defined subtype accepted in the updated WHO criteria. The 
authors acknowledge that this classification system is imperfect and of little prognostic 
benefit, citing the need for more reproducible data before further changes can be made. The 
standard of care for ependymoma is maximal safe resection followed by focal radiation 
therapy. However, some studies suggest that in a subset of patients with ependymoma, 
surgery alone without radiation or chemotherapy may suffice.45 Emerging classification 
schemes based on methylation profiling data46 yield improved prognostic significance 
relative to conventional histologic grading and will be important to incorporate into future 
preclinical models and clinical trials targeting these pediatric CNS malignancies.47
IMAGING
Concern for radiation exposure in developing children continues to drive the integration of 
imaging and radiation therapy to make treatment of pediatric brain malignancies safer and 
more targeted. Several diagnostic imaging techniques have been reported that aid in the 
classification and prediction of outcomes in pediatric brain tumors. For example, advanced 
magnetic resonance imaging (MRI) techniques such as diffusion tensor imaging (DTI) and 
dynamic susceptibility-weighted contrast-enhanced (DSC) perfusion have proven useful in 
glial tumors, particularly in their surgical management.48-51 Positron emission tomography 
(PET) is an imaging modality that enables noninvasive quantitation of biochemical processes 
such as glucose metabolism and oncogenic drivers such as receptor tyrosine kinases.52 The 
development of novel radiotracers for use in combination with PET improves delineation of 
active tissue within heterogeneous CNS tumors such as gliomas. By applying PET tracers 
specifically targeting factors linked to glioma-associated inflammation, such as the 
translocator protein (TSPO) and matrix metalloproteinases (MMP), Zinnhardt et al. 
characterized the tumor micro-environment in a murine model of human glioma non-
invasively, which matched histological findings.53 This method provided information that 
could not be detected by a single tracer and/or MRI alone, informing similar PET-based 
diagnostic approaches to characterize pediatric CNS malignancies.
Another perfusion-imaging technique, arterial spin labeling (ASL), represents an 
intriguiging alternative to MRI-based approaches such as DSC. In ASL, radiofrequency 
pulses are used to label endogenous protons within the arterial blood in order to measure 
cerebral blood flow, circumventing the need for intravenous gadolinium contrast agents, 
such as those required for DSC. In rare cases where the use of intravenous infusions of 
contrast agents may be contraindicated in the pediatric population (e.g., nephrogenic 
systemic fibrosis associated with acute and/or chronic renal impairment), ASL may provide 
similar data that may be useful in guiding clinical decision making for these patients.54
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PROMISING TUMOR PROFILING TECHNIQUES
In this section, novel molecular profiling techniques with the potential to migrate rapidly 
from preclinical settings into common clinical practice are discussed. These technologies are 
quickly reaching Clinical Laboratory Improvement Amendment (CLIA) approved status and 
impacting patient care. Note that the clinical utility of molecular biomarkers has already 
been established for a variety of cancers, including glioma, and specific well-established 
assays have had their analytical validity demonstrated for detection of those mutations in 
patient samples.55 Markers for glioma include: 1p/19q codeletion, analyzed by fluorescence 
in situ hybridization (FISH), array comparative genomic hybridization (aCGH), and 
multiplex ligation-dependent probe amplification (MPLA);56 IDH mutation established by 
immunohistochemistry (IHC), and DNA sequencing;57, 58 and MGMT methylation 
identified by methylation-specific (MS)-PCR, MS-pyrosequencing, and MS-MPLA.59
Molecular classification has also impacted the understanding of CNS primitive 
neuroectodermal tumors (CNS-PNETs), aggressive embryonal tumors occurring mostly in 
the pediatric population. These CNS malignancies often present challenges in 
neuropathological diagnosis due to a lack of defining molecular markers and histological 
overlap with other high-grade neuroepithelial tumors. Five subcategories of CNS-PNETs 
had been described by the WHO based on morphological features but more recent studies 
indicated that CNS-PNETs are molecularly heterogeneous, pointing to the need to classify 
this group better. To address this issue, Sturm et al. analyzed genome-wide DNA 
methylation profiles of tumors that had been institutionally classified as CNS-PNETs and 
found that over half of the samples did not form a distinct cluster, but rather displayed 
molecular profiles indistinguishable from other well-defined CNS tumor entities. From the 
remainder of the original CNS-PNETs, four new classifications were suggested based on 
genetic, histopathological, and clinical features of the tumor.60 Additionally, Johann et al. 
recently identified that atypical teratoid/rhabdoid tumors (AT/RTs), another group of 
pediatric CNS malignancy with poor prognoses, are comprised of three distinct epigenetic 
subgroups, with distinct clinical characteristics and regulatory networks that can potentially 
be targeted therapeutically.61 These studies reinforce the expanding importance of 
considering molecular profiling data when assigning a diagnosis to a CNS neoplasm given 
that this decision directs the selection of appropriate therapies to target aggressive pediatric 
brain cancers.
To address the issue of intratumoral heterogeneity in designing a treatment or assigning 
prognosis upon diagnosis, single-cell RNA-seq has been implemented as a useful technique 
to understand the tumor ecosystem and the diversity of cells therein.62 Patel et al. reported 
using the previously developed Smart-seq technique to profile 430 cells from five different 
primary glioblastomas, obtaining single cell full-length transcriptomes.63 Their results 
corroborate the idea that these tumors present variable expression of diverse transcriptional 
programs with regards to oncogenic signaling, proliferation, complement/immune response, 
and hypoxia. They also show that different glioblastoma subtype classifiers are found within 
different cells of a single tumor, an observation that may be critical for prognosis and choice 
of treatment protocols.64
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To address the challenges faced by low-input samples when using the aforementioned 
techniques, a portable, low-cost platform called Seq-Well has been developed by Gierahn et 
al. that enables high throughput, parallel single-cell RNA sequencing.65 This microwell-
based platform utilizes barcoded mRNA (mRNA) capture beads while single cells are sealed 
in subnanoliter wells by a semipermeable membrane that permits efficient cell lysis and 
transcript capture (Figure 2). Similar microfluidic approaches for single-cell multiplex 
processing are being developed, such as valve- and droplet-based platforms.66 Although the 
array of applications for these emerging techniques is vast, one may envision that they could 
be applied to a variety of cancer cells to understand tumor heterogeneity for the benefit of 
patient care.
While these increasingly precise technologies transition to the clinic, assessing genomic and 
epigenomic modifications that may have important implications in cancer biology still 
requires days to weeks for sample processing. Eukirchen et al. have validated the utility of a 
pocket-sized nanopore sequencing device that is capable of detecting copy number variants, 
point mutations, and methylation profiling within just 1 day for the analysis of brain cancer 
biopsies.67 Nanopore sequencing evaluates and interprets changes in ionic currents observed 
when single DNA or RNA molecules pass through a nanometer-size protein pore that can 
discriminate between nucleotides.68, 69 This platform can generate copy number variation 
data as well as detect single-base modifications, such as methylation profiles,70 concurrently 
in a single sequencing run. Even though this method has lower throughput than other 
technologies, it can yield ~0.1× genome coverage within 6 h and it is unique in that it 
enables low-cost, real-time reads outside of a laboratory setting. Furthermore, this platform 
was able to distinguish gliomas, medulloblastomas, and brain metastases of different 
primary sites from patient brain tumor biopsy samples, with copy number and epigenetic 
profiles that correlated well with matched microarray data.67
Even though many of the technologies discussed have not been applied widely to pediatric 
CNS malignancies, Ramkissoon et al. confirmed that a multiplexed targeted exome-based 
sequencing (OncoPanel) in combination with a clinical genome-wide aCGH assay 
(OncoCopy) can provide critical information for the treatment of pediatric brain tumors, by 
alerting pediatric oncologists to potential clinically relevant targets.71 These CLIA-certified 
platforms are a promising example of the clinical utility and validity of these emerging 
technologies.72 A novel genetic algorithm-based random forest modeling technique has also 
been developed that enables reduction in the complexity of large gene disease signatures.73 
This method has been explored for glioblastoma multiforme (GBM) samples, but it could 
potentially applied to other CNS neoplasms in order to facilitate interpretation of the 
increasing body of nucleotide-level information about these cancers. Other novel, potentially 
applicable methods of individualized analysis include the utilization of CRISPR-Cas9 to 
conduct large-scale genetic screening74 and patient-derived xenografts, which enable tumor 
profiling and drug screening.75 Some recent studies have translated pediatric tumor gemonic 
data to the clinic and were successful in identifying actionable findings that guided treatment 
approaches in a substantial proportion of the studied population, including in solid CNS 
tumors.76-78
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Finally, tumor-associated short noncoding RNAs found in CSF or blood are also thought to 
provide important insight into brain tumor biology due to the differences found between 
expression profiles in healthy individuals and patients (Figure 3). The aforementioned next-
generation sequencing platforms could be applied to analyze and to determine their utility in 
the diagnosis of pediatric brain malignancies and in disease surveillance.79
RADIATION THERAPY
Radiation therapy has been used for years in the treatment of childhood brain tumors and 
continues to be a mainstay in the management of some pediatric CNS malignancies. 
However, patients subjected to high doses of radiation are at increased risk of neurocognitive 
damage, growth arrest, damage to the cerebral vasculature and endocrine glands, inner ear 
dysfunction, as well as development of secondary cancers. Many efforts are therefore aimed 
at improving the precision and efficacy of radiation therapy treatments while reducing risks.
80, 81
 One such modality is proton beam therapy, which is an alternative to photons to deliver 
therapeutic radiation to treat CNS tumors.82, 83
Both proton and photon radiotherapy function by depositing energy in cells, which causes 
damage to the cellular DNA through the formation of free radicals; when DNA damage is 
not repaired, the cell dies. Tumor cells are known for having decreased capacity for DNA 
damage repair, which makes them more susceptible to damage and death through this 
method. However, normal cells are not entirely spared in the process and thus are also 
subjected to short- and long-term toxicity; therefore, reducing exposure of normal tissue to 
radiation is critically important (Figure 4).84
Proton therapy has only recently been used in pediatric cases, demonstrating equivalent 
efficacy with the potential for reduced side effects.85 The key is that the properties of proton 
beams allow decreased doses to normal tissues surrounding the tumor when compared to 
conventional photon therapy.86 Trials using this technique have shown mixed results in terms 
of local control, progression-free survival and avoidance of decreased IQ or overall adaptive 
skills.87-92 This therapy has been used for CNS germ cell tumors,88 localized ependymomas,
89
 low-grade gliomas,90 medulloblastomas,91 chordomas,93 and craniopharyngiomas.93
Other charged particle therapy technologies being developed utilize neutrons and carbon 
ions, but have not yet been implemented for pediatric tumors. Image-guided radiation 
therapy has also become increasingly common, and provides great improvements in 
radiotherapy accuracy. These techniques utilize high-quality images to guide target 
visualization with millimeter precision. Heightened precision enables reduction in the area 
of healthy tissue affected by therapy.84, 94
Nanoparticles have been developed in recent years that can work synergistically with 
radiation therapy to improve outcomes for brain tumor treatment. One of these approaches is 
boron neutron capture therapy, which relies on selectively concentrating boron compounds 
in tumor cells and then subjecting them to epithermal neutron beam radiation, thus 
depositing a large dose gradient between tumor cells and normal cells.95 Many other groups 
have also explored the use of gold nanoparticles to radiosensitize tumor cells. These efforts 
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have shown promising results in murine animal models of various brain tumors and include 
gold nanoparticles on their own,96, 97 coated with gadolinium chelates,98 pH-sensitive 
tumor-targetting peptides 99 and even in conjunction with superparamagnetic iron oxide in 
micelles;100 one study reports that silver nanoparticles can outperform gold nanoparticles for 
in vitro radiosensitization of glioma cells.101 Other groups have been successful in 
sensitizing brain tumor cells using nanoparticles that silence genome components. For 
instance, Zhang’s group has conducted nanoparticle-mediated siRNA knockdown of the 
DNA repair enzyme apurinic endonuclease 1 (Ape1) in a murine model of glioblastoma 102 
and in pediatric ependymoma and medulloblastoma cells in vitro, reporting improvements in 
circumventing radiation resistance in these tumors.103, 104
MOLECULAR THERAPY
Whereas conventional chemotherapy indiscriminately targets rapidly dividing cells, leading 
to a host of adverse effects, researchers are now seeking to exploit tumor-specific molecular 
pathways. One of the major challenges in pediatric neurooncology today is the paucity of 
efficacious treatments that target the growing list of molecular aberrations identified by 
increasingly sophisticated genomic and epigenomic technologies.105 Other treatments, while 
promising in their scientific rationale, have not demonstrated clinical benefit. Here, we 
briefly review a selection of targeted agents for some of the previously outlined tumors; the 
discussed, currently open clinical trials for pediatric brain tumors are listed in Table 1.
Embryonal Tumors.
For instance, a phase II trial evaluated vismodegib, a first-in-class smoothened receptor 
antagonist targeting the SHH pathway, demonstrating safety and possible activity in 
pediatric patients with recurrent SHH subtype medulloblastoma.106 The phase II SJMB12 
trial is currently stratifying patients with medulloblastoma based on clinical risk and 
molecular subtype, evaluating whether patients with low-risk Wnt tumors can be treated 
with lower doses of radiation and chemotherapy without impacting survival.107 TB-403, a 
monoclonal antibody against placental growth factor that showed activity in a murine 
medulloblastoma model,108 is currently being evaluated in a phase 1 and phase 2 trial in 
pediatric patients with relapsed or refractory medulloblastoma ().
Atypical teratoid rhabdoid tumor (AT/RT), a rare pediatric CNS embryonal tumor defined by 
biallelic inactivation of the INI-1 locus,109 is associated with a grim prognosis despite 
multimodal therapy.110 An ongoing phase I trial () is currently evaluating the effects of 
tazemetostat (an EZH2 inhibitor) in patients with relapsed or refractory INI1-negative 
malignancies, which include AT/RT. A phase II trial () is studying the effects of the auroa A 
kinase inhibitor alisertib in pediatric patients with AT/RT.
Gliomas.
Gene expression profiles of gliomas have been analyzed, searching for potentially 
exploitable driver mutations as the number of clinical trials investigating targeted therapies 
continues its rapid expansion.111, 112 As previously mentioned, sequencing of pediatric 
gliomas have identified mutations in the genes encoding histones 3.1 and 3.3, as well as 
Mochizuki et al. Page 9
ACS Chem Neurosci. Author manuscript; available in PMC 2019 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
chromatin modifiers ATRX and DAXX. Histones play an integral part in the packaging of 
DNA within cells, regulating its expression at the epigenetic level.113 Given their frequency, 
researchers are attempting to utilize these mutations as targets for therapy. For example, a 
multihistone deacetylase inhibitor, panobinostat, subsequently showed therapeutic efficacy 
in H3.3K27M mutant diffuse midline glioma cell culture and xenograft models,114 and is 
currently undergoing a phase I trial in children (). Another phase I trial is evaluating 
H3.3K27M peptide vaccine conjugated with tetanus toxoid () in pediatric patients with 
diffuse midline glioma.
Other studies include a recently completed phase I trial of crenolanib (), a PDGFR inhibitor, 
in patients with recurrent, high-grade glioma and diffuse midline glioma and a molecular 
profiling individualized treatment plan trial for diffuse midline glioma (). Hopefully, these 
more targeted and personalized medicine approaches will result in improved outcome for 
these patients in the near future.
Epithelial growth factor receptor (EGFR) is overexpressed in a subset of astrocytic pediatric 
gliomas,115 and can be targeted by agents such as erlotinib, which demonstrated tolerability 
in a phase I study in pediatric patients with brainstem glioma,116 but little effect in phase II.
117
 Multiple studies have evaluated a host of other agents with promise, but found little 
clinical benefit, including tipifarnib, a farnesyltransferase inhibitor, was studied in children 
with newly diagnosed diffuse midline gliomas but demonstrated no clinical advantage.118 
Enzastaurin, a protein kinase Cβ/PI3K/Akt pathway inhibitor, which showed some promise 
in a phase I pediatric trial.119
A frequent mutation identified in pediatric low-grade gliomas (LGG) involves BRAF, a gene 
that encodes a crucial enzyme involved in cell survival and growth signaling.30 Case reports 
have suggested some efficacy of vemurafenib against BRAFV600E mutant LGG in children;
120, 121
 an early phase I trial is currently underway (). Promising results have also emerged 
from a phase I study of selumetinib, a MEK1 inhibitor, in pediatric patients with recurrent or 
refractory LGG.122 In vitro and in vivo model systems of BRAF mutant LGG lend support 
to combination regimens such as PLX4720 (a BRAF inhibitor) plus selumetinib, or mTOR 
with MEK blockade.123, 124 These findings in part motivate a currently open clinical trial 
exploring the therapeutic role for combination MEK and BRAF inhibition for pediatric 
HGGs ().
Tuberous sclerosis, a genetic disorder that affects multiple organ systems, leads to 
overactivation of the mammalian target of rapamycin (mTOR) signaling cascade, can result 
in subependymal giant cell astrocytoma with biallelic mTOR dysregulation.125 Everolimus, 
an mTOR inhibitor, demonstrated significant, sustained reductions in subependymal giant 
cell astrocytoma volumes in a phase III trial of patients with tuberous sclerosis.126-128
Ependymal Tumors.
More than 75% of pediatric ependymomas coexpress ERBB2 and ERBB4;129 
overexpression of VEGF has been associated with poor survival.130 A phase II trial 
combined lapatinib, a selective ERBB1 and ERBB2 inhibitor, and bevacizumab in children 
with recurrent/refractory ependymoma, demonstrating tolerability, but no effect. However, 
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the authors note that bevacizumab monotherapy has not been shown to be efficacious in 
pediatric cases of recurrent ependymoma and that intratumoral lapatinib concentrations were 
below the threshold needed to inhibit the epidermal growth factor receptor (EGFR) and 
ERBB receptors.131 Sequencing of pediatric, poor-prognosis posterior fossa ependymomas 
revealed a CpG island methylator phenotype that has demonstrated in vivo responsiveness to 
DNA and H3K27 methylation-targeting.132
Pediatric MATCH.
In July 2017, The National Cancer Institute (NCI) and the Children’s Oncology Group 
(COG) announced the opening of enrollment for a phase II precision medicine clinical trial, 
the NCI-COG Pediatric Molecular Analysis for Therapy Choice screening protocol 
(Pediatric MATCH, ). This trial will provide genetic testing for children with various types 
of tumors, including CNS neoplasms. Patients with mutations that may benefit from one of 
the more than eight targeted study drugs will be identified for potential directed therapy. 
Treatment arms that are currently enrolling include larotrectinib (a pan-TRK inhibitor), 
LY3023414 (a small-molecule inhibitor of class I PI3K isoforms), mTOR, and DNA-PK, 
plus six other arms. This strategy represents a novel shift in focus from blanket therapy for 
each disease to a focus on the particular molecular pathways specific to each patient’s case.
133
IMMUNOTHERAPY
Emerging therapies, including immune-targeted strategies, for CNS malignancies have 
mostly risen from the study of glioblastoma. Cancer immunotherapy encompasses a variety 
of approaches, with the potential to harness the specificity of adaptive immunity, mediated 
by T-cells and antibodies, as well as the diverse cytotoxic mechanisms of innate immunity. 
Immunotherapy strategies include active antitumor vaccination, adoptive transfer activated 
cytotoxic cells, and blockage of immune inhibitory checkpoints. Preclinical studies, as well 
as early clinical failures, stress the importance of a multimodal, combinatorial approach to 
integrating immunotherapy into cancer treatment. Unlike conventional cancer therapies, 
active immunotherapies hold the potential to induce immune memory.
Dendritic cells (DC) are the most potent antigen-presenting cells in the human immune 
system; as such, a number of studies have utilized dendritic cell-based immunotherapy in 
varied cancer types, including for CNS neoplasms. Three studies have evaluated its use in 
children with brain tumors, finding them to be safe and tolerable in pediatric patients; larger 
studies are needed to elucidate treatment effect.134-136 Another approach is to use 
engineered materials to deliver immune modulating molecules to tumors, cancer vaccines or 
host immune cells, one avenue being to induce DC activation and subsequent priming of 
cancer-specific T-cell responses.137, 138
Patients’ own T-cells can be engineered to seek out and to destroy tumor cells by attaching 
receptors with affinity to antigens specific to the cancer of interest. These chimeric antigen 
receptor (CAR) T-cells have demonstrated efficacy in hematologic malignancies such as 
acute lymphoblastic leukemia.139 CAR T-cell therapy has proven to be a more difficult 
venture in solid tumors and by extension, CNS neoplasms. In treating patients with 
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glioblastoma, researchers have attempted engineering CAR T-cells to target the tumor-
associated antigen interleukin-13 receptor alpha 2;140 epidermal growth factor receptor 
variant III-specific CAR T-cells have demonstrated efficacy in a murine model.141 Two 
major hurdles in utilizing CAR T-cell therapy for CNS tumors are trafficking and 
persistence:142 intratumoral T-cell delivery may require repeated intracranial injections, 
which may not be feasible in a child with a brainstem tumor. Attempts have been made to 
genetically modify CAR T-cells to respond more effectively to trafficking signals;143 
however, there is a significant need for improved delivery systems, particularly in a space as 
difficult to access as the CNS. One innovative platform that may be ported to pediatric CNS 
neoplasms is the CIVO microdosing system, which can precisely inject multiple standard-of-
care chemotherapy agents into cancerous lymph nodes (). Notably, CAR T-cells tend to lack 
long-term survival in the solid tumor microenvironment, often reaching a premature state of 
exhaustion due to lack of resources for energy production and a more mature phenotype.144 
One innovative engineering approach has been the development of artificial thymic 
organoids, which may enable the production of younger, more naïve, and efficacious T-cells 
for use in immunotherapy.145
Gene expression data have recently been utilized to identify patients with intratumoral 
cytokine profiles that may predict more robust responses to pembrolizumab, a PD-1 
monoclonal antibody that blocks a major pathway of tumor immune evasion, enabling 
patients’ own immune systems to eliminate cancerous cells more effectively.146 
Furthermore, studies have demonstrated that tumors with defects in mismatch repair 
pathways (and consequent accumulation of hundreds to thousands of somatic mutations) are 
more responsive to PD-1 blockade.147 This finding has been recapitulated in a study wherein 
two pediatric patients with recurrent, multifocal, biallelic mismatch repair deficient GBMs 
exhibited sustained responses to pembrolizumab.148
Woensel and colleagues designed siRNA targeting Galectin-1 loaded chitosan nanoparticles 
to silence Gal-1 in the tumor microenvironment. Gal-1 is overexpressed in GBM and drives 
chemo- and immunotherapy resistance. Intranasal delivery of these particles seemed to 
promote a switch in the tumor microenvironment composition with respect to myeloid and 
T-cells, as well as promote normalization of tumor vasculature and increased survival in the 
animal mouse model. Furthermore, combination of the particles with Temozolomide or 
immunotherapy (dendritic cell vaccination and PD-1 blocking) showed synergistic effects to 
improve mice survival outcomes.149 Vaccination therapies composed of peptides against 
glioma-associated antigens, which were identified to be overexpressed in LGGs, have also 
shown promise in children with recurrent LGGs.150 Myriad studies are currently evaluating 
various combinations of other immunotherapeutical approaches (e.g., , ).
NANOPARTICLES
Nanoparticle drug delivery platforms have been described in the literature as typically 
belonging to one of the following categories: liposomes, nanoparticle albumin-bound 
technology, polymeric nanoparticles (PNPs), and molecular targeted nanoparticles.11, 151, 152 
More recently, drug-encapsulated PNPs have showed promise in targeting aggressive 
pancreatic ductal adenocarcinoma cells.153 Nanoparticles targeting various cancers are 
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continuously being developed and have been described to accumulate preferentially in 
tumors due to the so-called enhanced permeability and retention (EPR) effect. This favorable 
effect is attributed to defective vascularization and reduced lymphatic drainage in the tumor 
microenvironment,154, 155 although it does not necessarily correlate with improvement in 
tumor cell uptake of these nanoparticles. Therefore, an employed strategy has been to 
modify the surface of PNPs for tumor-specific recognition and internalization.
Within the context of GBM, DNA aptamer probes have been selected in vitro that are able to 
bind to a variety of glioblastoma cells lines with dissociation constants in the nanomolar 
range, while showing little affinity for other cancer cells. Aptamers are short artificial, 
single-stranded oligonucleotides that bind with high affinity to their ligands by recognizing a 
specific three-dimensional structure.156-158 Since crossing the blood-brain barrier (BBB) 
poses a significant obstacle to delivering therapeutic molecules to the brain, a bifunctional 
aptamer has been developed that targets both the transferrin receptor in the BBB (for 
transcytosis) and the cancer cell surface receptor epithelial cell adhesion molecule, 
conferring specificity to the target cell. In vivo studies in mice showed successful 
penetration of the bifunctional aptamers into the brain.159
Monaco et al. have taken this idea one step further and developed PNPs with surface 
aptamers. A conjugated aptamer that specifically recognizes platelet-derived growth factor 
receptor β (PDGFRβ) on GBM cells was manufactured to act as a nanovector for the 
delivery of the chemotherapeutic drug dactolisib. In vivo studies were successful in inducing 
specific toxicity in U87MG GBM cells in mice, and these PNPs effectively cross the BBB to 
arrive at the target microenvironment.160
Gold nanoparticles (AuNPs) have been reported that were designed with surface peptides 
that target both epidermal growth factor and transferrin receptors on glioblastomas. These 
particles, which were loaded with a hydrophobic photo-sensitizer drug, showed superior 
specificity and intratumoral accumulation in glioblastoma cells as compared to untargeted 
and monotargeted AuNPs. In vivo and in vitro work showed increased selectivity and 
cytotoxicity in target cells, as they also cross BBB more effectively (Figure 5a,b).10
Nanodiamond drug delivery platforms have also been evaluated for intracranial tumor 
treatment. Xi et al. described a system which consisted of doxorubicin, a chemotherapeutic 
agent not usually considered for treatment of brain malignancies due to its poor BBB 
penetration, reversibly bound to nanodiamonds for sustained functional drug release, while 
resulting in reduced myelosuppresion.161 The nanodiamond-doxorubicin complexes were 
used with convection enhanced delivery, which is a well-described method to open the BBB 
transiently. Their results indicate that this system has efficacious tumor killing capacity in a 
bioluminescent rodent glioma model, especially when combined with convection enhanced 
delivery, showing improved drug distribution and retention in brain tissue compared to 
controls.
Theranostic strategies where nanoparticles are configured to provide diagnostic information 
and to deliver therapeutic nanoparticles have played important roles. Magnetic nanoparticles 
(MNPs) composed of ferromagnetic iron oxide (Fe3O4) can also be surface functionalized 
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with peptides or antibodies to target particular cancers and guided to a particular site using a 
magnetic field. If encapsulated with a drug, the MNPs can then release the agent at the 
desired site. This technique has been employed in in vivo models, both for therapeutic 
purposes as well as for MRI contrast enhancement, although BBB penetration still remains a 
challenge. Intracranial implantation of MNPs have also been used for targeted 
thermotherapy, in which temperature elevation (40–45 °C range) generated by an alternating 
magnetic field is used to cause cancer cell death.12-14
An interleukin (IL)-13 amino-coated gadolinium metallofullerene nanoparticle has been 
fabricated as an alternative to the commonly used gadolinium (Gd) containing materials 
used for MRI imaging. These nanoassemblies contain positively charged amino groups on 
their surfaces, which enable more efficient binding to the negatively charged phospholipid 
bilayers of cell surfaces compared to conventional negatively charged Gd contrast agents. 
This functionalized trimetallic nitride template endohedral metallofullerene (TNT EMF) was 
also conjugated with IL-13 (designated IL-13-Gd3 N@ C80(OH)x(NH2)y) peptide for 
specific targeting of GBM in a mouse model when delivered intravenously (Figure 5c).162 
Another group has developed Gd-functionalized nanographene oxide (NGO) nanoparticles, 
composed of poly(amidoamine) dendrimer-grafted gadolinium-functionalized nanographene 
oxide (Gd-NGO), that act as effective carriers for delivery of chemotherapeutic drugs and 
microRNAs to cancer cells also in a GBM mouse model. The particles could also be used as 
a contrast agent for MRI to explore BBB opening and the extent of drug delivery to target 
tissues.163
CONCLUSIONS AND PROSPECTS
Brain tumors continue to be a common oncologic diagnosis among the pediatric population, 
and remain the most common cause of childhood cancer-related mortality. While 
multimodal therapy with chemotherapy based on tumor classification has been the standard 
of care, the significant intratumoral heterogeneity and possibly debilitating late effects 
demand a more individualized approach. New molecularly based tumor classification for 
some the most common childhood brain tumors and newly discovered molecular targets 
have resulted in multiple clinical trials using personalized or targeted approaches. Rapid 
advances in genetic sequencing, imaging and therapy delivery, such as small molecules 
targeting specific aberrant pathways, microfluidic devices for single-cell processing, targeted 
radiotracers, and nanodiamond systems now offer unprecedented precision in tailoring 
therapy for each patient. The gap between new technologies and pediatric patients 
consequently looms especially large, and innovative means of bridging this gap are direly 
needed.164 Nevertheless, the striking need for individualized treatment has been 
demonstrably recognized in the raft of new personalized medicine institutes that have 
opened in recent years. Nowhere is this more important than in pediatric oncology, to enable 
every opportunity for leading basic scientists and clinicians to interact and to drive 
multidisciplinary efforts targeting the eradicatation of the scourge of cancer and the 
potentially devastating effects of its treatment.
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LGG low-grade glioma
MNP magnetic nanoparticle
MRI magnetic resonance imaging
mRNA mRNA
MS methylation-specific
mTOR mammalian target of rapamycin
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Figure 1. 
(a) Incidence of pediatric (age 0–19) central nervous system (CNS) tumors by histological 
subtype. Of the three main categories, gliomas are the most common (53.1% of diagnoses), 
followed by embryonal tumors (13.8%) ependymal tumors (5.8%). (b) Average annual age-
adjusted mortality rate of all primary brain and CNS tumors in comparison to other common 
cancers for children age 0–14 years. Reprinted from ref 20 by permission of Oxford 
University Press, Copyright 2016.
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Figure 2. 
(a) In Seq-Well, cells are obtained from complex tissues or clinical biopsies, and digested to 
form a single-cell suspension. Barcoded mRNA capture beads are added to the surface of a 
microwell device, settling into wells by gravity, and then a single-cell suspension is applied. 
The device is sealed using a semipermeable membrane that confines cellular mRNAs within 
wells while allowing efficient buffer exchange. Liberated cellular transcripts hybridize to the 
bead-bound barcoded poly deoxythymine (dT) primers that contain a cell barcode and a 
unique molecular identifier (UMI) for each transcript molecule. After hybridization, the 
beads are removed from the array and bulk reverse transcription is performed to generate 
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single-cell cDNAs attached to beads. Libraries are then made by a combination of 
polymerase chain reaction (PCR) and tagmentation, and then are sequenced. Afterward, 
single-cell transcriptomes are assembled in silico using the cell barcodes and UMIs. (b) 
Equipment and arrays used to capture and lyse cells, respectively, in Seq-Well. Scale bar = 
100 µm. (c) Sequencing mix of human and mouse cells demonstrates distinct transcript 
mapping and single-cell resolution. (d) Number of trancsripts and (e) genes detected in 
single-cell libraries generated by Seq-Well or Drop-seq. (f) Representative single-cell RNA-
seq of cancer and noncancer cells in six oligodendrogliomas. On the left, copy number 
variant profiles inferred from single-cell RNA-seq and DNA whole-exome sequencing of the 
six oligodendrogliomas. On the right, analysis of copy number variants identified two 
subclones of cells in tumors identified as MGH36 and MGH97. Panels (a)–(e) reprinted 
from ref 62 by permission from Macmillan Pubishers Ltd.: Nature Methods, Copyright 
2017. Panel (f) reprinted from ref 165 by permission from Macmillan Publishers Ltd.: 
Nature, Copyright 2016.
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Figure 3. 
Tumor and serum microRNA-720 expression in individual glioblastoma multiforme (GBM) 
patients. PCR-based microRNA microarrays and real-time qPCR were performed in 
triplicate on complementary DNA amplicons created from RNA extracted from each GBM 
tumor specimen and intraoperative serum sample using a human serum albumin-
microRNA-720 probe. Blue bars indicate mean tumor microRNA-720 fold-change 
expression, red bars indicate mean serum microRNA-720 fold-change expression. Asterisk 
(*) denotes >35-fold higher expression than the normative standard. Figure courtesy of A. C. 
Wang, preliminary data.
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Figure 4. 
(a) Illustration of helical tomotherapy as an intensity-modulated radiation therapy device 
where a linear accelerator continuously revolves around the patient, while slowly advancing 
the patient through the plane of rotation. For radiation therapy dose delivery, a collimator is 
used to allow only sections of the fan beam to reach the patient. The collimator pattern 
changes as a function of gantry position, which provides many degrees of freedom to deliver 
highly conformal dose distributions. (b) Representative dose volume histograms comparing 
conventional three-dimensional conformal radiotherapy (dashed line) versus intensity-
modulated radiotherapy (solid line) plans for a patient with a left parietal lobe tumor. Note 
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the dose reduction for uninvolved parts of the brain. (c) Comparison of dose distribution 
using a proton beam. Note that ionization increases as the proton beam enters the patient, 
reaches intended dose at the tumor, then declines as velocity decreases. (d) Comparison of a 
photon- and a proton-based radiation therapy plan for a pediatric patient with a 
supratentorial ependymoma. Representative axial, coronal, and sagittal slices are shown for 
each plan. Approximate percentage isodoses are shown for reference in the axial slices. 
PTV: planning target volume. Brain, GTV: total brain without gross tumor volume. External, 
PTV: total tissue volume without planning target volume. IMRT: intensity-modulated 
radiotherapy. Panel (b) is reprinted from ref 81 with permission from Elsevier, Copyright 
2007. Panel (c) is reprinted from ref 83 with permission from Taylor & Francis Ltd., http://
www.tandfonline.com, Copyright 2010. Panel (d) is reprinted from ref 80 by permission 
from Taylor & Francis Ltd., http://www.tandfonline.com on behalf of Acta Oncologica 
Foundation, Copyright 2013.
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Figure 5. 
(a) Schematic illustrating the design of a dual-targeted gold nanoparticle (AuNP) system 
used to target glioblastoma (GBM) cells. The particles are functionalized with multiple 
receptor binding peptides to address intratumoral heterogeneity of GBM populations and the 
photosentizer phthalocyanine 4. (b) Transmission electron microscope image of hydrophobic 
gold nanoparticles used to prepare dual-targeted AuNPs. Scale bar = 100 nm. (c) Schematic 
illustrating nanoparticle targeting of U-251 glioblastoma cells. Localization of the 
gadolinium-tagged nanoparticles to glioblastoma cells implanted into mouse models is 
monitored via magnetic resonance imaging. Panels (a) and (b) reprinted with permission 
from ref 10. Copyright 2015 American Chemical Society. Panel (c) reprinted with 
permission from ref 162. Copyright 2015 American Chemical Society.
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